Douglas Kerr
CIK 1814189 · Head of R&D and CMO · last filed 2026-10-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GBIO price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
301 BINNEY STREET, SUITE 401
CAMBRIDGE, MA 02142
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DYN | Head of R&D and CMO | 170,564 | $16.05 | $2.74M | -$325.8K | 14 | 2026-10-22 |
| Generation Bio Co. (GBIO) Delisted | CHIEF MEDICAL OFFICER | 38,563 | $5.34 | $205.9K | -$1.55M | 16 | 2024-01-31 |
Recent Filings · Page 2 of 4
38 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-17 | DYN | Grant (A) | +85,000 | $0 | EDGAR |
| 2025-12-05 | DYN | Notice (144) Officer · Planned Dec 5, 2025 Sold: Form 4 filed Dec 5, 2025 |
−880 | -$18.2K | EDGAR |
| 2025-12-05 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−880 | -$18.2K | EDGAR |
| 2025-09-08 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−4,425 | -$58.8K | EDGAR |
| 2025-09-04 | DYN | Notice (144) Officer · Planned Sep 4, 2025 Sold: Form 4 filed Sep 8, 2025 |
−4,552 | -$60.4K | EDGAR |
| 2025-07-18 | DYN | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−1,342 | -$17.9K | EDGAR |
| 2025-06-05 | DYN | Notice (144) Officer · Planned Jun 5, 2025 Sold: Form 4 filed Jun 6, 2025 |
−1,342 | -$17.9K | EDGAR |
| 2025-03-07 | DYN | Sell (S)10b5-1 Plan adopted Dec 4, 2024 |
−1,343 | -$15.9K | EDGAR |
| 2025-03-05 | DYN | Notice (144) Officer · Planned Mar 5, 2025 Sold: Form 4 filed Mar 7, 2025 |
−1,343 | -$16.0K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).